DefenCath's Sustained Growth: A Harbinger for the Pharmaceutical Industry? The recent earnings call from CorMedix Inc.
has sent shockwaves through the pharmaceutical industry, with many analysts hailing DefenCath as a breakout star. The company's first quarter revenue of $127.
4 million, driven by sustained demand and the full quarter contribution of the Melinta portfolio acquisition, is a testament to the enduring power of innovative medicines.